Alcon -- a unit of Novartis (NYSE: NVS) -- presented positive results from its second Phase II clinical study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE